Echo Neurotechnologies

About Echo Neurotechnologies

Echo Neurotechnologies Corporation is a neurotechnology firm focused on developing brain-computer interfaces (BCIs) to address severe neurological disabilities. The company was officially incorporated on December 11, 2023, and is headquartered in San Francisco, California. It was founded by Dr. Edward Chang, a prominent neurosurgeon who also serves as the company's CEO and is the chairman of the neurosurgery department at the University of California, San Francisco (UCSF). Dr. Chang's extensive background in brain implant technology, including a notable 2023 project that enabled a paralyzed woman to communicate using AI, directly informs the company's direction.

The company operates in the therapeutic devices and healthtech market, specifically within the brain-machine interface sector. Its primary business involves creating neuroscience products designed to restore functions like conversational communication for patients with severe paralysis. The core of its product offering is an implantable BCI system. This system involves surgically placing electrodes on the brain to capture neural signals. These signals are then decoded by advanced software, potentially leveraging AI, to enable users to control external devices, such as computers or robotic limbs, with their thoughts. A key application demonstrated in research connected to the founding team is the conversion of neural activity into spoken language through a digital avatar, highlighting the technology's potential to restore communication.

Echo Neurotechnologies targets patients with conditions that result in severe physical limitations. The business model appears to be centered on the research, development, and eventual commercialization of these medical devices. In January 2025, the company secured approximately $50 million in a Series A funding round, with venture capital firm Andreessen Horowitz (a16z) as a key investor. This capital is intended to support the company's growth, research, and development efforts as it works towards clinical applications and competes in a field with other entities like Neuralink and Synchron.